SOURCE: Ablynx

February 18, 2009 12:18 ET

ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2008 WITH WEBCAST

GHENT, BELGIUM--(Marketwire - February 18, 2009) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, plans to announce its full year results for 2008 on 24 February 2009 after market closure.

Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the full year results for 2008 will be presented, followed by a Q&A session. This event will be held on Wednesday, 25 February 2009 at 2.00 p.m. CET.

The conference call will be webcast live and can be accessed through the home page of the Ablynx website (www.ablynx.com). Shortly thereafter, a replay version of the webcast will be accessible on our website under Investor Relations > Newsroom > Events and Presentations: http://www.ablynx.com/investorrelations/english/newsroom_eventsandpresentations.php.

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 200 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Nanobodies® have been generated against more than 100 different disease targets. Importantly the Nanobodies® which naturally exist in llamas have a very high homology with humans. Efficacy data has been obtained in over 25 in vivo models for Nanobodies® against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies® for healthcare applications. It has exclusive and worldwide rights to more than 50 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies®.

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t:  +44 (0)20 7866 7857
f:  +44 (0)20 7866 7900
e:  ablynx@collegehill.com

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:  +32 (0)9 262 00 07
m:  +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:  +32 (0)9 262 00 75
m:  +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.


Copyright © Hugin AS 2009. All rights reserved.

Contact Information